elevatebio ipo：ElevateBio Stock $1.16
ElevateBio Stock $1.16
BecauseElevateBioisprivatelyheld,itsstockisnotavailableforpurchasethroughpublicstockexchangesliketheNYSEorNasdaq.Retailinvestorscannot ...。其他文章還包含有：「ElevateBioAnnounces$401MillionSeriesDFinancingto...」、「ElevateBio」、「InvestInElevateBioStock」、「SoftBank」、「HowDidElevateBioManageToNab$401MInThis...」、「2年獲投8.5億美元，Biotech公司「裂變式創業」成細胞和基因...」、「【新興領...
查看更多 離開網站
ElevateBio Announces $401 Million Series D Financing to ...
https://elevate.bio
ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth. Proceeds enable expansion and scale of ElevateBio's cell and ...
ElevateBio
https://elevate.bio
We provide the tools, time, and environment to innovate and accelerate development of life-saving Cell and gene therapies.
Invest In ElevateBio Stock
https://equityzen.com
ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.
SoftBank
https://www.reuters.com
ElevateBio said on Wednesday it had raised $401 million in a new funding round led by a fund run by Matrix Capital Management.
How Did ElevateBio Manage To Nab $401M In This ...
https://news.crunchbase.com
ElevateBio, a Massachusetts-based gene therapy startup, announced on Wednesday it raised $401 million in Series D funding.
2年獲投8.5億美元，Biotech公司「裂變式創業」成細胞和基因 ...
https://precisionthera.com
美東時間3 月15 日，美國生物技術公司ElevateBio 宣佈完成了5.25 億美元C 輪融資，本輪投資由Matrix Capital Management、軟銀願景基金二期和富達管理研究 ...
【新興領域2023.10焦點】2023Q3全球健康醫療投資掃描
https://findit.org.tw
（2）2023Q1-Q3全球健康醫療Pre-IPO投資力道仍不振，平均規模為近六年最低。 ... ElevateBio(D輪/4.01億美元)、提供家庭慢性腎臟病(CKD)和末期腎臟病 ...
ElevateBio hits 2023 high with $401M for cell
https://www.fiercebiotech.com
ElevateBio's $401 million haul has already bumped the RNA company's $300 million series A out of the running for the largest private biotech fundraise of 2023.
ElevateBio Stock Price, Funding
https://www.cbinsights.com
ElevateBio has raised $1.246B over 5 rounds. ElevateBio's latest funding round was a Series D for $401M on May 24, 2023.